The exploration of novel Alzheimer’s therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches-Reference-Cited by-同舟云学术

The exploration of novel Alzheimer’s therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches

Published:2019-01 Issue: Volume:109 Page:2513-2526
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Hassan Mubashir,Raza Hussain,Abbasi Muhammad Athar,Moustafa Ahmed A.,Seo Sung-Yum

Funder

National Research Foundation of Korea

Ministry of Education

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference227 articles.

1. Genetic underpinnings in Alzheimer’s disease - a review;Moustafa;Rev. Neurosci.,2018

2. Alzheimer’s disease as neurodegenerative disorder;Zabłocka;Postepy. Hig. Med. Dosw.,2006

3. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention;Qiu;Dialogues Clin. Neurosci.,2009

4. Probing the biology of Alzheimer’s disease in mice;Ashe;Neuron,2010

5. Alzheimer mechanisms and therapeutic strategies;Huang;Cell,2012

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug repurposing for diabetes mellitus: In silico and in vitro investigation of DrugBank database for α-glucosidase inhibitors;International Journal of Biological Macromolecules;2024-06

2. Relación entre el Uso de Toxinas Derivadas de Venenos de Animales Aplicadas a Moléculas para Tratamiento de Alzheimer;Estudios y Perspectivas Revista Científica y Académica;2024-05-28

3. Molecular Dynamics and Binding Energetics of Fluspirilene With BACE1: Implications for Alzheimer's Disease Intervention;Peptide Science;2024-04-04

4. Synthesis, Kinetics and Computational Explorations of 4‐Phenylpiperazine Bearing N‐(Aryl)‐3‐substituted‐benzamides as Auspicious Tyrosinase Inhibitors;Chemistry & Biodiversity;2024-03-13

5. Repurposing FDA‐approved drugs to target malaria through inhibition of dihydrofolate reductase in the folate biosynthesis pathway: A prospective approach;Journal of Cellular Biochemistry;2024-02-12